reverse transcriptase inhibitor


Also found in: Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to reverse transcriptase inhibitor: NNRTI, NRTI

reverse transcriptase inhibitor

n. Abbr. RTI
Any of various antiviral compounds that interfere with the activity of the enzyme reverse transcriptase, which is found especially in retroviruses such as HIV. These compounds are divided into two classes: those that are nucleoside analogs (nucleoside reverse transcriptase inhibitors) and those that are not nucleoside analogs (non-nucleoside reverse transcriptase inhibitors).
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.reverse transcriptase inhibitor - an antiviral drug that inhibits the action of reverse transcriptase in retroviruses such as HIV
antiviral, antiviral agent, antiviral drug - any drug that destroys viruses
NNRTI, non-nucleoside reverse transcriptase inhibitor - an antiviral drug used against HIV; binds directly to reverse transcriptase and prevents RNA conversion to DNA; often used in combination with other drugs
NRTI, nucleoside reverse transcriptase inhibitor - an antiviral drug used against HIV; is incorporated into the DNA of the virus and stops the building process; results in incomplete DNA that cannot create a new virus; often used in combination with other drugs
References in periodicals archive ?
If successfully developed and approved by regulatory authorities, the treatment is to offer an option to HIV patients to switch from a standard three-drug therapy to a two-drug, nucleoside reverse transcriptase inhibitor sparing antiviral regimen.
Rifampicin, a key component of TB treatment, is a potent inducer of drug metabolism and decreases plasma concentrations of many co-administered drugs, including non-nucleoside reverse transcriptase inhibitors, protease inhibitors and integrase inhibitors.
Reverset was also shown to be effective in patients with virus resistant to other commonly used nucleoside analog reverse transcriptase inhibitors (NRTIs), including viruses harboring multiple thymidine analog mutations (TAMS), including the M41L and L210W mutations, and the L74V and M184V mutations.
Many people did not achieve durable virologic benefits from these drugs, mainly because they had previously taken and developed resistance to the nucleoside analog reverse transcriptase inhibitors (NRTIs).
High AST also was predictive of severe hepatotoxicity in the first 6 months of therapy among patients using a nonnucleoside reverse transcriptase inhibitor (OR 2.
Reverse transcriptase inhibitors copy the genetic code of HIV and helps it replicate into additional human cells.
Separately, the company signed an agreement with Yamasa Corporation based in Choshi, Japan, to develop EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine), a novel nucleoside reverse transcriptase inhibitor candidate that is in preclinical studies and has shown antiviral activity toward highly resistant HIV strains.
Currently reverse transcriptase inhibitors represent over 50% of the global sales of HIV drugs which in 2004 was in excess of US$6 billion.
In addition, patients taking a protease inhibitor were more likely to have hyperglycemia compared to patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI or "non-nuke").
The randomized study of 122 patients with HIV added a protease inhibitor to a standard regimen of two nucleoside reverse transcriptase inhibitors and one nonnucleoside reverse transcriptase inhibitor for 62 patients who continued the induction regimen for 24-32 weeks in order to lower viral load to less than 50 copies/mL.
Today Vitalea Science announced it had received a National Institute of Allergy and Infectious Disease (NIAID) grant to develop and test assays to quantify intracellular uptake of the active metabolite of a nucleoside reverse transcriptase inhibitor (NRTI) drug that can be applied to children and neonates.
According to Chimerix deal, Merck will have to develope and commercialize CMX157, an investigational oral nucleoside reverse transcriptase inhibitor which is presently in Phase I clinical development.

Full browser ?